Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 103Neoplasms, Plasma Cell 11Immunoglobulin Light-chain Amyloidosis 11Recurrence 10Leukemia, Myeloid, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 3Neoplasms 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Hodgkin Disease 2Hematologic Diseases 2Corneal Diseases 2Blood Protein Disorders 2Amyloidosis 2Acute Kidney Injury 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Plasmacytoma 1

Interventions

Propranolol 2daratumumab 1Watchful Waiting 1Surgical Procedures, Operative 1Simvastatin 1Observation 1DNA 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangioma, Cavernous, Central Nervous System × daratumumab × Clear all
NCT07026604 2025-06-18

CCM-DS01

Beijing Tiantan Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡